Read-GeneS.A.Active
Research and experimental development on biotechnology
KRS: 0000242181 NIP: 8522464257 REGON: 32010563600000
Overview
Registry date
2005-09-27
Share capital
$159,238.38
Activity description
Read-Gene is a company focused on the commercialization of methods for detecting, preventing, and treating various types of malignant tumors. They offer innovative DNA tests that help in the accurate prevention and quicker initiation of treatment for individuals with genetic predispositions to cancer. The company collaborates with medical professionals from the International Center for Hereditary Cancers at the Pomeranian Medical University in Szczecin.
Registered address
Akacjowa 2, 71-253 Szczecin, Poland
Website
read-gene.comWebsite active
Email
Email address current
Accounts
Registered as a VAT taxpayer on 2010-09-30.Active
- 35 1240 3927 1111 0010 0756 5222
Authorized Representatives
Ownership
Subsidiaries
| Name | Shares | Share value | % in company | |
|---|---|---|---|---|
| Innowacyjna Medycynasp. z o.o. | 1 | 1,350.62 USD | 100% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| BiotechnaS.A. | $2,465,682.50 | bsbiotechna.com | |
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | |
| GenomtecS.A. | $931,086.83 | genomtec.com | |
| GenxoneS.A. | $542,750.94 | genxone.eu | |
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | |
| BiottsS.A. | $372,115.60 | biotts.com | |
| Medicofarma BiotechS.A. | $330,956.61 | medicofarmabiotech.pl | |
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | |
| FcbiotechS.A. | $148,945.77 | fcbiotech.pl | |
| UveraS.A. | $155,384.29 | uvera.eu |
FAQ
Last updated: 2026-07-04